Journal of Clinical Oncology
Articles in this Issue
Prediction of response to neoadjuvant dose-dense chemotherapy in luminal breast cancer using a genomic risk probability model.
e12627 Background: Response to neoadjuvant chemotherapy (NACT) in hormone receptor-positive, HER2-negative (ER+/HER2-) bre...
Exploring neural correlates of chemotherapy-induced peripheral neurotoxicity (CIPN) and the impact of exercise: A URCC NCORP nationwide phase II randomized controlled trial (RCT).
11023 Background: More than half of patients with cancer receiving neurotoxic chemotherapy (e.g., taxane, platinum, vinca...
Insights from an artificial intelligence (AI)–powered cancer navigation platform: Digital support and treatment decision confidence.
e13674 Background: Patients with cancer are often overwhelmed with the complexity of their diagnosis, treatment options, a...
Patient preference for subcutaneous vs. intravenous immune therapy (PSI-Immune).
TPS1678 Background: Immune checkpoint blockade (ICB) has improved outcomes for patients (pts) with advanced solid tumors....
Reducing cost and complexity in tumor-informed MRD by combining patient probe panels using Enspyre.
e14533 Background: Tumor-informed minimal residual disease (MRD) assays track patient-specific variants, achieving higher...
Use of multiplexed functional profiling to reveal antiproliferative activity of PARP inhibitors missed by cytotoxicity-only assays in primary ovarian cancer tissues.
e15123 Background: PARP inhibitors (PARPi) are primarily used as maintenance therapy in ovarian cancer, where clinical ben...
Enhancing colonoscopy outcomes: A systematic review and meta-analysis of randomized controlled trials evaluating artificial intelligence–assisted adenoma and polyp detection.
e15519 Background: Colorectal cancer (CRC) remains a leading cause of cancer-related mortality worldwide. Colonoscopy is t...
Adjuvant chemotherapy versus chemoradiotherapy in high-risk extrahepatic cholangiocarcinoma and gallbladder carcinoma: A National Database analysis.
e16298 Background: High-risk extrahepatic biliary tract cancers (BTC), including extrahepatic cholangiocarcinoma (EHCC) an...
National trends and racial disparities in diffuse large B-cell lymphoma mortality in the United States, 1999–2023.
e19092 Background: Advances in immunochemotherapy and cellular treatment have improved outcomes for diffuse large B-cell l...
Circulating tumor DNA for characterizing intratumor heterogeneity and outcomes in metastatic colorectal cancer.
3585 Background: Intratumor heterogeneity (ITH) drives CRC resistance, yet tissue-based assessments remain limited. ctDNA...
Patterns of unscheduled oncologic consultations at a tertiary center in North Africa: Are we treating emergencies or filling gaps?
e13622 Background: Improvements in cancer treatment have improved survival, transforming many malignancies into chronic di...
The applicability of the 21-gene assay to inform chemotherapy benefit in lymph node–positive hormone receptor–positive male breast cancer.
e12509 Background: There are no studies focusing on the applicability of the 21-gene Oncotype Dx Recurrence Assay (RS) ass...
Assessment of ctDNA tumor fraction and confidence in driver-negative liquid biopsy findings.
e15126 Background: Circulating tumor DNA (ctDNA) analysis enables non-invasive detection of tumor-specific genomic alterat...
Comparative outcomes of hypofractionated versus conventional radiotherapy following mastectomy for breast cancer: A systematic review and meta-analysis.
e12544 Background: Previous meta-analyses have compared hypofractionated versus conventional postmastectomy radiotherapy,...
Real-world resource use and cost in patients treated with originator or biosimilar rituximab in a large U.S. insurance claims database.
11159 Background: Rituximab-pvvr, Rituximab-arrx, and Rituximab-abbs are monoclonal antibodies approved by the FDA as bios...
ctDNA dynamics and prognostic value during first-line treatment of metastatic colorectal cancer: Analysis from the phase 3 PARADIGM study.
3573 Background: The phase 3 PARADIGM trial showed overall survival (OS) and tumor response advantages of anti-EGFR (panit...
Machine learning approach to identify HDL as a prognostic factor for melanoma immunotherapy.
e21531 Background: Melanoma immunotherapy faces challenges due to heterogeneous patient responses. Current predictive biom...
Real-world use of olaparib in US veterans with metastatic castration-resistant prostate cancer: Treatment patterns and outcomes.
5071 Background: Olaparib, a targeted therapy for metastatic castration-resistant prostate cancer (mCRPC), has demonstrate...
Cost per patient per month for a median of 3 months: Real-world value signals of KRAS <sup>G12C</sup> inhibitors in U.S. claims for non–small cell lung cancer.
e23078 Background: KRAS G12C inhibitors have demonstrated efficacy in clinical trials for KRAS G12C–mutated non–small cell...
Temporal trends and sociodemographic disparities in place of death among adults with pancreatic cancer in the United States (1999–2023).
12035 Background: Location of death is a critical quality metric for pancreatic cancer due to its rapid trajectory and hig...
Efficacy of Lu-PSMA–based treatment strategies in metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.
e17114 Background: Lutetium-177-PSMA-617 (Lu-PSMA) has demonstrated significant survival benefit in metastatic castration-...
Artificial intelligence–enabled analysis of unstructured EHR data for identification of actionable HER2-low breast cancer phenotypes.
e13029 Background: Antibody-drug conjugates (ADCs) targeting HER2 have shown clinical effectiveness in breast cancer, even...
Genomic landscape and evolutionary dynamics of <i>RAS</i> alterations in glioma: A large-scale clinicopathologic analysis.
e14077 Background: Gliomas are molecularly heterogeneous. RAS alterations ( KRAS ,...
Longitudinal follow-up after identification of variants of uncertain significance in highly penetrant cancer predisposition genes.
10607 Background: ASCO and the NCCN recommend that patients with variants of uncertain significance (VUS) in hereditary ca...
Capivasertib plus fulvestrant in Chinese patients with HR+/HER2− advanced breast cancer: Interim analysis of CAPItrue.
1088 Background: After disease progression on cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) plus endocrine therapy (ET)...